[go: up one dir, main page]

WO2009038756A3 - Compositions polypeptidiques d'élément nucléaire dispersé long et leurs procédés d'utilisation - Google Patents

Compositions polypeptidiques d'élément nucléaire dispersé long et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2009038756A3
WO2009038756A3 PCT/US2008/010883 US2008010883W WO2009038756A3 WO 2009038756 A3 WO2009038756 A3 WO 2009038756A3 US 2008010883 W US2008010883 W US 2008010883W WO 2009038756 A3 WO2009038756 A3 WO 2009038756A3
Authority
WO
WIPO (PCT)
Prior art keywords
line
methods
present
immune response
polypeptide compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/010883
Other languages
English (en)
Other versions
WO2009038756A2 (fr
Inventor
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Mario Ostrowski
R Bradley Jones
Ashish Agrawal
Frederick M Hecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J David Gladstone Institutes
University of California Berkeley
University of California San Diego UCSD
Original Assignee
J David Gladstone Institutes
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J David Gladstone Institutes, University of California Berkeley, University of California San Diego UCSD filed Critical J David Gladstone Institutes
Priority to MX2010003110A priority Critical patent/MX2010003110A/es
Priority to EP08832080A priority patent/EP2200637A4/fr
Priority to US12/677,278 priority patent/US20110046042A1/en
Priority to JP2010525831A priority patent/JP2010539901A/ja
Priority to CA2700115A priority patent/CA2700115A1/fr
Priority to AU2008301888A priority patent/AU2008301888A1/en
Priority to CN2008801164478A priority patent/CN101969987A/zh
Priority to BRPI0817209-9A2A priority patent/BRPI0817209A2/pt
Publication of WO2009038756A2 publication Critical patent/WO2009038756A2/fr
Publication of WO2009038756A3 publication Critical patent/WO2009038756A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)

Abstract

La présente invention porte sur des polypeptides LINE; et sur des compositions, contenant des compositions immunigènes, incluant un polypeptide LINE objet. La présente invention porte sur un acide nucléique recombinant incluant une séquence nucléotidique codant pour un polypeptide LINE objet. Une composition objet est utile pour stimuler une réponse immunitaire des lymphocytes T contre un peptide LINE. La présente invention porte en outre sur des procédés de stimulation d'une réponse immunitaire chez un individu contre une cellule infectée par un rétrovirus ou un lentivirus. La présente invention porte en outre sur des procédés de traitement de cancers qui sont associés à des tissus dans lesquels des polypeptides LINE sont exprimés de façon aberrante. L'invention porte également sur des procédés de traitement de troubles, mettant en jeu la diminution d'une réponse immunitaire contre un polypeptide LINE.
PCT/US2008/010883 2007-09-20 2008-09-19 Compositions polypeptidiques d'élément nucléaire dispersé long et leurs procédés d'utilisation Ceased WO2009038756A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2010003110A MX2010003110A (es) 2007-09-20 2008-09-19 Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.
EP08832080A EP2200637A4 (fr) 2007-09-20 2008-09-19 Compositions polypeptidiques d'élément nucléaire dispersé long et leurs procédés d'utilisation
US12/677,278 US20110046042A1 (en) 2007-09-20 2008-09-19 Long Interspersed Nuclear Element Polypeptide Compositions and Methods of Use Thereof
JP2010525831A JP2010539901A (ja) 2007-09-20 2008-09-19 長鎖散在反復配列ポリペプチド組成物およびその使用方法
CA2700115A CA2700115A1 (fr) 2007-09-20 2008-09-19 Compositions polypeptidiques d'element nucleaire disperse long et leurs procedes d'utilisation
AU2008301888A AU2008301888A1 (en) 2007-09-20 2008-09-19 Long interspersed nuclear element polypeptide compositions and methods of use thereof
CN2008801164478A CN101969987A (zh) 2007-09-20 2008-09-19 长散布核元件多肽组合物及其使用方法
BRPI0817209-9A2A BRPI0817209A2 (pt) 2007-09-20 2008-09-19 Composições de polipeptídeo de elemento nuclear intercalado longo e métodos de uso das mesmas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97399307P 2007-09-20 2007-09-20
US60/973,993 2007-09-20

Publications (2)

Publication Number Publication Date
WO2009038756A2 WO2009038756A2 (fr) 2009-03-26
WO2009038756A3 true WO2009038756A3 (fr) 2009-05-14

Family

ID=40468692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/010883 Ceased WO2009038756A2 (fr) 2007-09-20 2008-09-19 Compositions polypeptidiques d'élément nucléaire dispersé long et leurs procédés d'utilisation

Country Status (11)

Country Link
US (1) US20110046042A1 (fr)
EP (1) EP2200637A4 (fr)
JP (1) JP2010539901A (fr)
KR (1) KR20100075483A (fr)
CN (1) CN101969987A (fr)
AU (1) AU2008301888A1 (fr)
BR (1) BRPI0817209A2 (fr)
CA (1) CA2700115A1 (fr)
MX (1) MX2010003110A (fr)
RU (1) RU2010115088A (fr)
WO (1) WO2009038756A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (fr) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Sequences polynucleotidiques et polypeptidiques intervenant dans le processus de remodelage osseux
US8647640B2 (en) 2009-06-24 2014-02-11 Richard E. COWART Vaccine compositions and methods of use to protect against infectious disease
WO2012048113A2 (fr) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarqueurs de cancer
US20150219662A1 (en) * 2012-06-28 2015-08-06 University Of Louisville Research Foundation, Inc. Use of protein line-1 orf-1 as a biomarker for cancer
CA2928851A1 (fr) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anticorps anti-siglec-15
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
JP6830660B2 (ja) * 2015-04-03 2021-02-17 国立大学法人京都大学 がんの治療薬のスクリーニング方法
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
US20250290065A1 (en) * 2019-10-16 2025-09-18 King Abdullah University Of Science And Technology Methods for modulating human l1 retrotransposons rna and compositions for use therein
EP4081309A4 (fr) * 2019-12-26 2024-01-17 The Johns Hopkins University Amélioration de l'expression d'orf2p codée en ligne-1 pour des agents thérapeutiques contre le cancer
US20230220005A1 (en) * 2020-06-02 2023-07-13 Tokyo Women's Medical University S100a8-inhibiting peptide and disease therapeutic agent containing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039952A2 (fr) * 2002-10-25 2004-05-13 Five Prime Therapeutics, Inc. Procedes d'utilisation de polypeptides humains codes par des polynucleotides
US20070031445A1 (en) * 1995-10-20 2007-02-08 Sanderson Sam D Compositions and methods for enhancing immune responses mediated by antigen-presenting cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280108A (en) * 1991-09-27 1994-01-18 United States Of America Antibodies to p40
CN1315379A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人L1因子p40蛋白12和编码这种多肽的多核苷酸
CN1315332A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——l1－12和编码这种多肽的多核苷酸
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
CN1339450A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——转座元蛋白14.41和编码这种多肽的多核苷酸
CN1339478A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——人l1因子orf2相关蛋白10.78和编码这种多肽的多核苷酸
CN1343776A (zh) * 2000-09-19 2002-04-10 上海博德基因开发有限公司 一种新的多肽——dna聚合酶9.02和编码这种多肽的多核苷酸
CN1352094A (zh) * 2000-11-06 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人l1元件类蛋白19.80和编码这种多肽的多核苷酸
CN1425684A (zh) * 2001-12-19 2003-06-25 复旦大学 一种多肽——人反转录转座40蛋白－12.76和编码这种多肽的多核苷酸
CA2520768A1 (fr) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Procedes d'identification de variants optimaux d'epitopes peptidiques
WO2005049789A2 (fr) * 2003-05-28 2005-06-02 The Johns Hopkins University Gene de retrotransposon synthetique mammiferes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031445A1 (en) * 1995-10-20 2007-02-08 Sanderson Sam D Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
WO2004039952A2 (fr) * 2002-10-25 2004-05-13 Five Prime Therapeutics, Inc. Procedes d'utilisation de polypeptides humains codes par des polynucleotides

Also Published As

Publication number Publication date
BRPI0817209A2 (pt) 2015-03-10
CA2700115A1 (fr) 2009-03-26
US20110046042A1 (en) 2011-02-24
KR20100075483A (ko) 2010-07-02
MX2010003110A (es) 2010-05-19
WO2009038756A2 (fr) 2009-03-26
AU2008301888A1 (en) 2009-03-26
EP2200637A2 (fr) 2010-06-30
JP2010539901A (ja) 2010-12-24
RU2010115088A (ru) 2011-10-27
CN101969987A (zh) 2011-02-09
EP2200637A4 (fr) 2011-10-19

Similar Documents

Publication Publication Date Title
WO2009038756A3 (fr) Compositions polypeptidiques d'élément nucléaire dispersé long et leurs procédés d'utilisation
WO2008011120A3 (fr) Compositions polypeptidiques rétrovirales endogènes humaines et leurs procédés d'utilisation
WO2010003065A3 (fr) Axmi-115, axmi-113, axmi-005, axmi-163 et axmi-184 : protéines insecticides et leurs procédés d'utilisation
EP2470559A4 (fr) Compositions de facteur ix de coagulation et leurs procédés de fabrication et d'utilisation
WO2013040093A3 (fr) Compositions de peptide-2 de type glucagon et leurs procédés de fabrication et d'utilisation
WO2010099365A3 (fr) Protéines pesticides et procédés d'utilisation associés
TN2012000393A1 (en) Agonist dr5 binding polypeptides
EP2650311A3 (fr) Séquences d'acides aminés dirigées contre des cytokines hétérodimériques et/ou leurs récepteurs et polypeptides les comprenant
EP4450523A3 (fr) Protéines de fusion de liaison, conjugués protéine de fusion-médicament de liaison, conjugués xten-médicament et leurs procédés de fabrication et d'utilisation
TN2011000283A1 (en) Human cgrp receptor binding proteins
PH12012502272A1 (en) Biological materials related to her3
MX2014001070A (es) Gen plaguicida axmi279 y sus metodos de uso.
EP2937419A3 (fr) Gènes de delta-endotoxine axmi221z axmi222z, axmi223z, axmi224z et axmi225z et leurs procédés d'utilisation
MX362999B (es) Gen de la delta-endotoxina axmi345 y sus metodos de uso.
WO2009102421A3 (fr) Agents thérapeutiques cibles basés sur des protéines fabriquées qui se lient au récepteur de l’egf
MX2014000993A (es) Gen de la toxina axmi270 y sus metodos de uso.
MX351526B (es) Proteinas variantes axmi205 y sus metodos de uso.
WO2008066752A3 (fr) Substances thérapeutiques à base de protéines modifiées ciblées sur des récepteurs de tyrosine kinases, dont l'igf-ir
WO2010138263A3 (fr) Nouveaux virus adéno-associés (aav) et leurs utilisations
EP3372617A3 (fr) Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
WO2011150133A3 (fr) Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
WO2005121331A3 (fr) Polypeptides galnact2 tronques et acides nucleiques
MX362455B (es) Gen de la toxina axmi335 de bacillus thuringiensis y sus metodos de uso.
WO2015088937A3 (fr) Gènes de toxines axmi477, axmi482, axmi486 et axmi525 et procédés d'utilisation de ceux-ci
WO2008137881A3 (fr) Protéines d'ehrlichia ewingii, acides nucléiques, et procédés pour leur utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880116447.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08832080

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 204504

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008301888

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2700115

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/003110

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010525831

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2262/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107007557

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008301888

Country of ref document: AU

Date of ref document: 20080919

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008832080

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010115088

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12677278

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0817209

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100322